Pfizer takes scalpel to early-phase pipeline, slicing off RSV, eczema, sickle cell and cancer programs

Pfizer is ringing the changes as it exits the second quarter, tossing out a midstage pneumococcal vaccine candidate and a handful of phase 1 assets including a respiratory syncytial virus (RSV) prospect it picked up in last year’s ReViral takeover.